STEMCELL Technologies Launches mTeSR™ Plus, a Next-Generation Culture System for Human ES and iPS Cell Maintenance
VANCOUVER, British Columbia--(BUSINESS WIRE)--Jan 23, 2019--STEMCELL Technologies has released mTeSR™ Plus, an enhanced version of mTeSR™1, the most widely published feeder-free human pluripotent stem cell (hPSC) maintenance medium. The new medium has undergone successful beta testing with several members of the Stem Cell COREdinates group and has completed rigorous in-house validation testing.
Designed to promote a more consistent cell culture environment through sustained medium pH and stabilized components including FGF2, mTeSR™ Plus prevents the rapid onset of acidosis. This helps avoid conditions that have been associated with DNA damage, genomic instability, and growth arrest in hPSCs. The stabilization enhancements allow for greater hPSC expansion rates, enhanced culture morphology, and truly versatile feeding schedules including the option to skip weekends.
“With the launch of mTeSR™ Plus, STEMCELL is positioned to set new industry standards in the pluripotent stem cell research field,” says Dr. Allen Eaves, President and CEO of STEMCELL Technologies. “We are dedicated to offering our customers versatile, high-quality products that fit their ever-evolving research needs. I’m excited to see the future research breakthroughs that mTeSR™ Plus will support.”
mTeSR™ Plus joins STEMCELL’s extensive portfolio of feeder-free media for the maintenance of human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells. All products are developed and manufactured using STEMCELL Technologies’ rigorous raw material screening and quality control processes.
About STEMCELL Technologies
STEMCELL Technologies supports life sciences research with more than 2,500 specialized reagents, tools, and services. We offer high quality cell culture media, cell separation technologies, instruments, accessory products, and educational resources that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190123005072/en/
CONTACT: Andrew Gaffney, PhD, Senior Product Manager
STEMCELL Technologies Inc
KEYWORD: NORTH AMERICA CANADA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CARDIOLOGY MEDICAL DEVICES ONCOLOGY PHARMACEUTICAL
SOURCE: STEMCELL Technologies Inc
Copyright Business Wire 2019.
PUB: 01/23/2019 06:00 AM/DISC: 01/23/2019 06:01 AM